NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough

Novavax (NVAX) stock has been surging due to biotech stocks hitting their highest levels since the pandemic, driven by a Moderna-Merck mRNA cancer therapy trial success. Despite Novavax not being directly involved, it benefited from sector-wide optimism. The company reported a 76% year-over-year revenue decline but topped analyst estimates with $56.7 million revenue, beating earnings estimates.

Adjusted loss per share came in lower than expected at $0.32. Product sales rose 76% to $18.9 million, while Sanofi-related revenue totaled $36 million. Gross margin remained robust at 75%, and combined GAAP R&D and SG&A expenses fell 21% year-over-year. NVAX is now trading near $8.79, up over 10% in a single session and 34% YTD.

The company raised its full-year 2026 revenue guidance to $235 million to $275 million, citing strengthening momentum across its partnership pipeline. Management remains optimistic about its leaner operating model and continued push toward sustainable profitability by 2028.